Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1101 patients with newly diagnosed CMML.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The current study validates the predictive performance of the BLAST and BLAST-Mol risk models in a large two-center international cohort with a total of 1101 patients with newly diagnosed CMML.
The current study validates the predictive performance of the BLAST and BLAST-Mol risk models in a large two-center international cohort with a total of 1101 patients with newly diagnosed CMML.
APA
Fathima S, Alsugair A, et al. (2025). Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.. American journal of hematology, 100(12), 2426-2430. https://doi.org/10.1002/ajh.70080
MLA
Fathima S, et al.. "Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.." American journal of hematology, vol. 100, no. 12, 2025, pp. 2426-2430.
PMID
40996347
Abstract
The current study validates the predictive performance of the BLAST and BLAST-Mol risk models in a large two-center international cohort with a total of 1101 patients with newly diagnosed CMML.
MeSH Terms
Humans; Leukemia, Myelomonocytic, Chronic; Male; Female; Aged; Middle Aged; Blast Crisis; Adult; Aged, 80 and over; Risk Factors; Prognosis
같은 제1저자의 인용 많은 논문 (2)
- CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia.
- CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.